Laboratoire de parasitologie, Centre Nationale de Référence du Paludisme, World Health Organization Collaborating Center for surveillance of antimalarial drug resistance, Institut Pasteur de la Guyane, Cayenne, French Guiana.
Ecole Doctorale n°587, Diversités, Santé, et Développement en Amazonie, Université de Guyane, Cayenne, French Guiana.
Elife. 2020 May 12;9:e51015. doi: 10.7554/eLife.51015.
Antimalarial drug resistance has historically arisen through convergent mutations in parasite populations in Southeast Asia and South America. For the past decade in Southeast Asia, artemisinins, the core component of first-line antimalarial therapies, have experienced delayed parasite clearance associated with several mutations, primarily C580Y. We report that mutant has emerged independently in Guyana, with genome analysis indicating an evolutionary origin distinct from Southeast Asia. C580Y parasites were observed in 1.6% (14/854) of samples collected in Guyana in 2016-2017. Introducing C580Y or R539T mutations by gene editing into local parasites conferred high levels of artemisinin resistance. growth competition assays revealed a fitness cost associated with these variants, potentially explaining why these resistance alleles have not increased in frequency more quickly in South America. These data place local malaria control efforts at risk in the Guiana Shield.
抗疟药物耐药性在历史上是通过东南亚和南美洲寄生虫种群的趋同突变产生的。在过去的十年中,青蒿素作为一线抗疟疗法的核心成分,经历了与多种突变相关的寄生虫清除延迟,主要是 C580Y 突变。我们报告说,突变已经在圭亚那独立出现,基因组分析表明其进化起源与东南亚不同。2016-2017 年在圭亚那采集的 854 个样本中,有 1.6%(14/854)观察到 C580Y 寄生虫。通过基因编辑将 C580Y 或 R539T 突变引入当地寄生虫中,赋予了高水平的青蒿素耐药性。生长竞争测定显示,这些变异与一定的适应性成本相关,这可能解释了为什么这些耐药等位基因在南美洲没有更快地增加频率。这些数据使圭亚那盾地区的疟疾控制工作面临风险。